Neos Therapeutics on Monday earned Food and Drug Administration approval for its attention-deficit/hyperactivity disorder drug Cotempla.
Cotempla is an extended-release orally disintegrating tablet intended to treat ADHD in patients ages 6 to 17 years. The pill dissolves in a patient's mouth with no need for water or chewing, according to a news release.
Neos plans to launch Cotempla as a portable blister pack this fall.
More articles on supply chain:
25 top supply chains in 2017, as ranked by Gartner
Baltimore's naloxone supply dwindling as opioid overdose rates surge
Patients seeking financial assistance for $750k Biogen drug must sign away PHI